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Abstracts / Osteoarthritis and Cartilage 21 (2013) S9–S62S12The expression of Dkk-1 by chondrocytes was high in the non calciﬁed
cartilage layers at baseline and in sham-operated knees, but greatly
decreased after partial meniscectomy from 4 weeks. Sclerostin and
sFRP-3 were expressed only in calciﬁed cartilage and increased with the
development of OA.
Conclusion: This in vivo study shows that in OA, the canonical Wnt
signaling pathway is mainly activated in subchondral bone, forming
osteophytes and synovium. Moreover, each Wnt antagonist has
a speciﬁc expression pattern in OA cartilage. Further studies are needed
to assess whether regulating Wnt activity in joint tissues can impact
cartilage loss in OA.7
IMPAIRED FRACTURE HEALING BY HIGHLY SELECTIVE COX-2
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Purpose: Non-steroidal anti-inﬂammatory drugs (NSAIDs) are widely
used for pain relief in osteoarthritis, after trauma and are used early
treatment of rheumatoid arthritis. More and more cyclooxygenase-2
selective NSAIDs are used because they induce fewer upper gastroin-
testinal complications. However, despite the positive applications of
these drugs there are also downsides to their use. In addition to the
previously described impairment of the osteogenic phase of endo-
chondral ossiﬁcation, we showed that NSAIDs have adverse effects on
the in vitro chondrogenic phase of endochondral ossiﬁcation as well.
We therefore hypothesized that highly selective COX-2 inhibition by
celecoxib impairs fracture healing not only in the osteogenic phase but
also in the chondrogenic phase in an in vivo rabbit model.
Methods: Fractures were simulated by the creation of a ‘critical size
defect’ in the left ulnas of 12 skeletally immature SPF New Zealand white
rabbits. Half of the rabbits received an oral dose of 10mg/kg celecoxib
each day from day 0. The control group was placebo treated. The
experiment was ended 25 days after initiation of the fractures.
After harvesting the ulnas were scanned using a micro-CT scanner
(micro-CT80, ScancoMedical, Bruettisellen Switzerland) and plain X-rays
were taken. Micro-CT images of the fracture region were used for Finite
Element Analysis (FEA) to determine the consolidation of the fractures.
Hereafter the ulnas were embedded in PMMA and 50mm thick sections
were cut for histological analysis. To determine the effect of celecoxib on
skeletal development, the growth plate region of ulnas from the
contralateral legwere decalciﬁed, embedded in parafﬁn and cut into 5mm
thick sections. The sections were haematoxylin stained and the total
growth plate thickness as well as thickness of the proliferative and
hypertrophic zones were determined. PGE2 concentrations in the plasma
(at the day of sacriﬁce) was determined using a speciﬁc ELISA.
Results: COX-2 inhibition by celecoxib was conﬁrmed by signiﬁcantly
decreased PGE2 levels in plasma of celecoxib-treated animals as
compared to control animals. The ulnar fractures in the rabbits which
were treated with celecoxib showed substantially less consolidation
than the fractures in the rabbits in the control group. On the plain X-rays
bigger gaps were observed in the fracture region than in the control
group. These ﬁndings were conﬁrmed by our micro-CT analysis.
Furthermore the FEA applied on the micro-CT datasets showed
a signiﬁcant decrease in compression stiffness of the fracture-region
and a decreasing trend in torsional stiffness, bending stiffness for
a moment around its x-axis and its y-axis. Histological sections of
the ulnar fractures showed a larger cartilaginous tissue fraction in the
fracture regions of the celecoxib-treated rabbits as compared to the
control group. Analysis of the ulnar growth plates showed a signiﬁcant
decrease in total growth plate thickness in the celecoxib- treated group.
When the proliferative and hypertrophic zones were scored separately,
no signiﬁcant difference was found between the proliferative zones,
however the hypertrophic zone was signiﬁcantly thinner in the cele-
coxib-treated group as compared to the control group.
Conclusions: We have shown that systemic COX-2 inhibition by cele-
coxib impairs fracture healing in an in vivo rabbit model. In additionwe
showed that chondrocyte hypertrophy in the ulnar growth plate is
inhibited. These ﬁndings suggest that the impaired fracture healing
might not be a speciﬁc consequence of impaired osteogenic phase, but
is at least in part a result of an effect of celecoxib on the chondrogenic
phase of endochondral ossiﬁcation.8
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Purpose: To evaluate the interaction of articular cartilage (AC) and
subchondral bone (SB) through analysis of osteoarthritis (OA)-related
genes of site-matched tissue.
Methods: We developed a novel method for isolating site-matched
overlying AC and underlying SB from three and four regions of interest
respectively from the human knee tibial plateau (n¼50). For each site,
the severity of cartilage changes of OAwere assessed histologically, and
the severity of bone abnormalities were assessed by microcomputed
tomography. An RNA isolation procedure was optimized that yielded
high quality RNA from site-matched AC and SB tibial regions. Q-PCR
analysis was performed to evaluate gene expression of 61 OA-associ-
ated genes for correlation with cartilage integrity and bone structure
parameters.
Results: A total of 27 (44%) genes were coordinately up or down
regulated in both tissues. The expression levels of 19 genes were
statistically signiﬁcantly correlatedwith the severity of AC degeneration
and changes of SB structure; these included: ADAMTS1, ASPN, BMP6,
BMPER, CCL2, CCL8, COL5A1, COL6A3, COL7A1, COL16A1, FRZB, GDF10,
MMP3, OGN, OMD, POSTN, PTGES, TNFSF11 and WNT1.
Conclusions: These results provide a strategy for identifying targets
whose modiﬁcation may have the potential to ameliorate pathological
alterations and progression of disease in both AC and SB simultaneously.
In addition, this is theﬁrst study, to ourknowledge, to overcome themajor
difﬁculties related to isolation ofhighqualityRNA fromsite-matched joint
tissues. We expect this method to facilitate advances in our under-
standingof the coordinatedmolecular responses of thewhole joint organ.
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RNASE MRP IS A NOVEL REGULATOR OF ENDOCHONDRAL
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Purpose: Mutations in the RMRP gene cause cartilage-hair hypoplasia
(CHH). CHH patients present with short stature (dwarﬁsm), sparse hair,
immunodeﬁciency and increased risk for malignancies. CHH is the ﬁrst
identiﬁed human disease caused by mutations in a small nucleolar
noncoding RNA molecule. RMRP RNA is the RNA subunit of the RNase
MRP complex, a macromolecular particle consisting of the RMRP RNA
and at least 7 different protein subunits (Rpp20, Rpp25, Rpp30, Rpp38,
Rpp40, Pop1 and Pop5). CHH-associated mutations in the RMRP gene
are thought to reduce its RNase enzymatic activity or to interfere with
its expression, however how this results in the development of CHH is
unknown. The most prominent phenotypic hallmark of CHH is
dwarﬁsm, suggesting that RNase MRP function is involved in develop-
ment of the growth plate. We therefore hypothesized that RNaseMRP is
involved in chondrogenic differentiation.
Methods: To investigate the expression of RNase MRP subunits during
chondrogenic differentiation in vivo, spatiotemporal expression of
